Myovant Sciences Ltd (MYOV) Receives Average Rating of “Buy” from Brokerages
Myovant Sciences Ltd (NASDAQ:MYOV) has received an average recommendation of “Buy” from the seven analysts that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $20.00.
A number of brokerages have recently weighed in on MYOV. JMP Securities reiterated an “outperform” rating and set a $25.00 price target (up previously from $23.00) on shares of Myovant Sciences in a report on Wednesday, October 4th. Robert W. Baird reissued a “buy” rating and set a $20.00 price objective on shares of Myovant Sciences in a research report on Wednesday, October 4th. Cowen and Company reissued a “buy” rating on shares of Myovant Sciences in a research report on Tuesday, October 3rd. Zacks Investment Research raised Myovant Sciences from a “sell” rating to a “hold” rating in a research report on Friday, August 25th. Finally, Evercore ISI initiated coverage on Myovant Sciences in a research report on Wednesday, August 16th. They set an “outperform” rating for the company.
Myovant Sciences (NASDAQ:MYOV) traded down 1.58% during trading on Thursday, hitting $13.10. The stock had a trading volume of 7,577 shares. The firm’s market cap is $797.06 million. The firm’s 50 day moving average is $13.96 and its 200 day moving average is $13.96. Myovant Sciences has a 1-year low of $9.92 and a 1-year high of $18.85.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Quantitative Systematic Strategies LLC acquired a new stake in Myovant Sciences during the second quarter valued at $165,000. Goldman Sachs Group Inc. acquired a new stake in Myovant Sciences during the second quarter valued at $174,000. Wells Fargo & Company MN boosted its position in Myovant Sciences by 331.9% during the first quarter. Wells Fargo & Company MN now owns 16,527 shares of the company’s stock valued at $194,000 after purchasing an additional 12,700 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Myovant Sciences by 36.3% during the first quarter. Bank of New York Mellon Corp now owns 23,784 shares of the company’s stock valued at $279,000 after purchasing an additional 6,330 shares during the last quarter. Finally, Swiss National Bank acquired a new stake in Myovant Sciences during the second quarter valued at $294,000.
About Myovant Sciences
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.
Receive News & Ratings for Myovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.